Evidence map›Paper›PMID 39195287›Full record

ArticleCells2024

Unexpected Expression and Function of FcεRI in Immortalized Breast Cancer Cells: A Cautionary Null Study.

Alexandria M Ashbaugh, David O Lyons, Carianna M Keyser, Nicholas A Pullen

Abstract read
In one paragraph

Article in Cells, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Genes · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Alexandria M AshbaughDepartment of Chemistry and Biochemistry, University of Northern Colorado, Greeley, CO 80639, USA.
David O LyonsDepartment of Biological Sciences, University of Northern Colorado, Greeley, CO 80639, USA.
Carianna M KeyserDepartment of Biological Sciences, University of Northern Colorado, Greeley, CO 80639, USA.
Nicholas A PullenDepartment of Biological Sciences, University of Northern Colorado, Greeley, CO 80639, USA.ORCID 0000-0002-4014-9278

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The high-affinity IgE receptor, FcεRI, is typically associated with type 2 effectors such as mast cells (MC). The relatively unique expression profile of FcεRI and accumulating evidence from pre-clinical and clinical settings, such as MC interactions with tumors, have led us to study MCs as a potential therapeutic target in breast cancer. Our work identified MCs interacting with tumor cells at primary sites using the 4T1 (BALB/c) adenocarcinoma model in vivo. However, this analysis was complicated by a surprising finding that the tumor cells intrinsically and strongly expressed FcεRI. We further studied the expression and function of FcεRI in breast cancer cells in vitro. The 4T1 cells expressed FcεRI to a level similar to mouse bone marrow-derived MC (BMMC). Additionally, two established breast cancer cultures derived from human T-47D cells, one estrogen-dependent (E3) and the other estrogen-withdrawn (EWD8), also expressed FcεRI with EWD8 cells showing the greatest abundance. Functional analyses indicated that IgE-mediated antigen stimulation did not elicit classic Ca

Indexed as

Breast NeoplasmsReceptors, IgEAnimalsCell Line, TumorFemaleGene Expression Regulation, NeoplasticHumansImmunoglobulin EInterleukin-6Mast CellsMiceMice, Inbred BALB CImmunoglobulin EInterleukin-6Receptors, IgEbreast cancerFcεRImast cell

Identifiers

PMID39195287
PMCPMC11352550

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.